FDA Brief

Company record

Harbin Jixianglong Biotech Co., Ltd.

1 FDA warning letter since 2023 and 2 recalls in the last 12 months.

Get an email the day FDA posts anything new about Harbin Jixianglong Biotech Co., Ltd..

Warning letters

  1. Harbin Jixianglong Biotech Co., Ltd.

    FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.

    High risk

Recalls

ReportedClassFirmProduct and reason
Mar 11 Class II Harbin Jixianglong Biotech Co., Ltd.
Drug
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer…
CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
Mar 11 Class II Harbin Jixianglong Biotech Co., Ltd.
Drug
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotec…
CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution